Mylan to manufacture Covid-19 treatment for India

CANONSBURG, Pa. — Mylan NV has received emergency use approval by the government of India for an injectable form of remdesivir for severely ill people with Covid-19.

Mylan (Nasdaq: MYL), which is run from its corporate offices at Southpointe, said it will start selling remdesivir 100 mg/vial under the brand name Desrem in India in July. Remdesivir is an antiviral medication developed by Gilead Sciences Inc. that has shown promise in treating severe Covid-19 cases. Mylan and Gilead (Nasdaq: GIL) have a deal to commercialize remdesivir in 127 countries around the world and the companies have worked to tackle public health problems before, including HIV.

Read more from our news partners at the Pittsburgh Business Times.

Hundreds of scientists say coronavirus is airborne, asks WHO to revise recommendations Hundreds of scientists say coronavirus is airborne, asks WHO to revise recommendations (NCD)

© 2020 Cox Media Group